ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Am
The purpose of this study is to: * Describe epidemiological and clinical characteristics, natural history and real-world clinical management of ATTR amyloidosis patients * Characterize the safety and effectiveness of patisiran and vutrisiran as part of routine clinical practice in the real-world clinical setting * Desc
| Condition(s) | Transthyretin-Mediated Amyloidosis, ATTR Amyloidosis |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | The purpose of this study is to: * Describe epidemiological and clinical characteristics, natural history and real-world clinical management of ATTR amyloidosis patients * Characterize the safety and effectiveness of patisiran and vutrisiran as part of routine clinical practice in the real-world clinical setting * Describe disease emergence/progression in pre-symptomatic carriers of a known disease-causing transthyretin (TTR) variant |
| Who can participate | Inclusion Criteria: * Diagnosis of ATTR amyloidosis or documented known disease-causing TTR variant for the cohort of pre-symptomatic carriers * Germany Only: Patients must be treated per the summary of product characteristics (SmPC) for any approved treatment for ATTR amyloidosis Exclusion Criteria: * Current enrollment in a clinical trial for any investigational agent |
| Sex | All |
| Lead sponsor | Alnylam Pharmaceuticals |
| Locations | La Jolla, California, United States; Los Angeles, California, United States; Jacksonville, Florida, United States; Iowa City, Iowa, United States; Kansas City, Kansas, United States; Baltimore, Maryland, United States (+34 more sites) |
| Start date | 2020-11-23 |
| NCT ID | NCT04561518 |
| Official listing | https://clinicaltrials.gov/study/NCT04561518 |